Clarkston Capital Partners LLC Invests $40.57 Million in Medpace Holdings, Inc. $MEDP

Clarkston Capital Partners LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 129,259 shares of the company’s stock, valued at approximately $40,569,000. Clarkston Capital Partners LLC owned approximately 0.46% of Medpace as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MEDP. Vulcan Value Partners LLC grew its position in shares of Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock valued at $99,159,000 after buying an additional 224,578 shares during the last quarter. Mawer Investment Management Ltd. boosted its stake in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after acquiring an additional 121,213 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Medpace by 79.3% during the second quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock worth $83,258,000 after purchasing an additional 117,301 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after purchasing an additional 105,807 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after purchasing an additional 102,015 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other Medpace news, President Jesse J. Geiger sold 21,503 shares of the business’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $8,934,900. The trade was a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Stephen P. Ewald sold 15,230 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $598.85, for a total transaction of $9,120,485.50. Following the sale, the general counsel directly owned 13,343 shares in the company, valued at $7,990,455.55. This represents a 53.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 310,767 shares of company stock valued at $185,879,561. Company insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Robert W. Baird set a $613.00 target price on shares of Medpace in a research report on Friday, October 24th. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and increased their price target for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Finally, Jefferies Financial Group raised their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $487.18.

Medpace Trading Down 0.9%

NASDAQ MEDP opened at $606.60 on Friday. The stock has a market capitalization of $17.09 billion, a price-to-earnings ratio of 42.42, a PEG ratio of 2.67 and a beta of 1.42. The business’s 50 day moving average is $558.59 and its two-hundred day moving average is $441.45. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.